Common Shares (Details Narrative) |
1 Months Ended | 12 Months Ended | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Feb. 25, 2026
USD ($)
$ / shares
shares
|
Nov. 21, 2025 |
Oct. 15, 2025
USD ($)
$ / shares
shares
|
Sep. 29, 2025
USD ($)
$ / shares
shares
|
Sep. 19, 2025
USD ($)
$ / shares
shares
|
Jul. 18, 2025
USD ($)
$ / shares
shares
|
Apr. 21, 2025
$ / shares
shares
|
Apr. 17, 2025
USD ($)
shares
|
Nov. 13, 2024
USD ($)
$ / shares
shares
|
Nov. 13, 2024
USD ($)
$ / shares
|
Nov. 05, 2024
USD ($)
$ / shares
shares
|
Sep. 17, 2024
USD ($)
$ / shares
shares
|
Apr. 12, 2024
USD ($)
$ / shares
|
Apr. 12, 2024
$ / shares
shares
|
Mar. 17, 2023
shares
|
Jan. 31, 2025
USD ($)
$ / shares
shares
|
Jun. 30, 2026
USD ($)
TradingDays
$ / shares
shares
|
Jun. 30, 2025
USD ($)
$ / shares
shares
|
Mar. 04, 2026
shares
|
Oct. 17, 2025
shares
|
Sep. 30, 2025
shares
|
Nov. 30, 2024
USD ($)
|
Nov. 04, 2024
shares
|
Jun. 30, 2024
$ / shares
shares
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Common stock, shares issued | 17,400,000 | 10,152,175 | 7,004,740 | 10,000,000 | 13,850,000 | 2,577,320 | 145,838,380 | 58,491,196 | 5,924,942 | 2,755,218 | ||||||||||||||
| Offering price of common shares issued in offering | $ / shares | $ 3.25 | $ 0 | $ 0 | |||||||||||||||||||||
| Offering price of common shares issued in offering | $ / shares | $ 5 | $ 9.34 | $ 6.15 | $ 5 | $ 1.7675 | $ 1.7675 | ||||||||||||||||||
| Net Proceeds | $ | $ 93,406,000 | $ 138,974,000 | $ 55,365,000 | $ 46,048,000 | $ 41,335,000 | $ 467,202,000 | $ 45,666,000 | |||||||||||||||||
| Common share description | On February 25, 2026, the Company issued and sold (a) 17,400,000 Common Shares at an offering price of $5.00 per Common Share and (b) 2,600,000 pre-funded Warrants (the “February Pre-Funded Warrants”) to purchase up to an additional 2,600,000 Common Shares at an offering price of $4.9999 per February Pre-Funded Warrant in a registered offering (the “February 2026 Offering”) under the Company's registration statement on Form S-3 (Registration No. 333-290837), pursuant to the Placement Agency Agreement between the Company and Maxim, dated February 24, 2026. On February 25, 2026 and March 4, 2026, the Company issued a total of 2,599,951 Common Shares in connection with the cashless exercise of all of the outstanding February Pre-Funded Warrants. The Company received net proceeds from the February 2026 Offering, after deducting placement agent fees and other offering expenses payable by the Company, of approximately $93,406. | On October 15, 2025, the Company issued and sold (a) 10,152,175 Common Shares at an offering price of $9.34 per Common Share and (b) 5,925,000 pre-funded Warrants (the “October Pre-Funded Warrants”) to purchase up to an additional 5,925,000 Common Shares at an offering price of $9.3399 per October Pre-Funded Warrant in a registered offering (the “October 2025 Offering”) under the Company's registration statement on Form S-3 (Registration No. 333-290837), pursuant to the Placement Agency Agreement between the Company and Maxim, dated October 13, 2025. On October 17, 2025, the Company issued 5,924,942 Common Shares in connection with the cashless exercise of all of the outstanding October Pre-Funded Warrants. The Company received net proceeds from the October 2025 Offering, after deducting placement agent fees and other offering expenses payable by the Company, of approximately $138,974. | On September 29, 2025, the Company issued and sold (a) 7,004,740 Common Shares at a public offering price of $6.15 per Common Share and (b) 2,755,260 pre-funded Warrants to purchase an aggregate of 2,755,260 Common Shares (the “September Pre-Funded Warrants”) at a public offering price of $6.1499 per September Pre-Funded Warrant in a confidentially marketed public offering (the “September 2025 Public Offering”) under the Company’s registration statement on Form S-3 (Registration No. 333-280176), pursuant to the Placement Agency Agreement between the Company and Maxim, dated September 26, 2025. On September 30, 2025, the Company issued 2,755,218 Common Shares in connection with the cashless exercise of all of the outstanding September Pre-Funded Warrants. The Company received net proceeds from the September 2025 Public Offering, after deducting placement agent fees and other offering expenses payable by the Company, of approximately $55,365. | On January 31, 2025, the Company closed an underwritten registered direct offering (the “January 2025 Offering”), pursuant to an underwriting agreement, dated January 29, 2025, with Maxim, as underwriter, pursuant to which the Company issued and sold 2,577,320 Common Shares, 2,577,320 Series A Warrants to purchase up to 2,577,320 Common Shares (the “January 2025 Series A Warrants”) and 1,288,660 Series B Warrants to purchase up to an additional 1,288,660 Common Shares (the “January 2025 Series B Warrants” and, together with the January 2025 Series A Warrants, the “January 2025 Warrants”). Each Common Share was sold together with one January 2025 Series A Warrant and one-half of one January 2025 Series B Warrant at a combined public offering price of $1.94. The gross proceeds from the January 2025 Offering were approximately $5,000 before deducting underwriting discounts and offering expenses. The January 2025 Warrants were classified as equity instruments, and accordingly, the net proceeds were allocated based on the relative fair values of the Common Shares and the January 2025 Warrants on the date of issuance, with $2,200 allocated to the fair value of the January 2025 Warrants and the balance of the proceeds of $2,800 allocated to Common Shares. The Company incurred total transaction costs related to the January 2025 Offering of $799, which were treated as share issuance costs at closing. The January 2025 Series A Warrants have an exercise price of $1.98 per underlying Common Share, are exercisable immediately, and will expire on August 2, 2027. The January 2025 Series B Warrants have an exercise price of $2.05 per underlying Common Share, are exercisable immediately, and will expire on January 31, 2029. | ||||||||||||||||||||
| Common stock shares | 5,925,000 | 2,755,260 | ||||||||||||||||||||||
| Number of share outstanding | 18,707,780 | |||||||||||||||||||||||
| Outstanding stock options vested | 53.30% | |||||||||||||||||||||||
| Aggregate number of common shares available for awards | 11,300,000 | |||||||||||||||||||||||
| Maximum annual compensation | $ | $ 750,000 | |||||||||||||||||||||||
| Intrinsic value of Options exercised | $ | 1,654,000 | |||||||||||||||||||||||
| Unrecognized compensation costs | $ | $ 1,540,000 | |||||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross | 2,282,500 | 945,000 | ||||||||||||||||||||||
| Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | $ 4.68 | $ 1.41 | ||||||||||||||||||||||
| Average grant-date fair value | $ / shares | $ 2.84 | $ 0.84 | ||||||||||||||||||||||
| Risk-free interest rate | 3.84% | 4.44% | ||||||||||||||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 76.80% | 67.30% | ||||||||||||||||||||||
| Expected option life in years | 4 years 7 months 6 days | 5 years | ||||||||||||||||||||||
| Share based compensation | $ | $ 4,441,000 | $ 789,000 | ||||||||||||||||||||||
| Warrants outstanding | 18,707,780 | |||||||||||||||||||||||
| Description of warrants | On November 13, 2024, the Company closed a non-brokered private placement (the “November 2024 Private Offering”), pursuant to binding subscription agreements with certain accredited investors as part of a non-brokered private placement of 2,199,602 units of the Company (the “November 2024 Units”). Each November 2024 Unit consisted of one Common Share, one Warrant (a “Series A Private Warrant”) to purchase one Common Share, and one-half of one Warrant (each whole such Warrant, a “Series B Private Warrant” and, together with the Series A Private Warrants, the “November 2024 Private Warrants”), with each Series B Private Warrant entitling the holder thereof to purchase one additional Common Share. Each November 2024 Unit was issued and sold at a price of $1.57. The gross proceeds of the November 2024 Private Offering were approximately $3,500 before deducting offering expenses. Certain directors and officers of the Company (the “Insider Investors”) purchased November 2024 Units at a price of $1.7675 per November 2024 Unit, which price includes $0.1975 per November 2024 Private Warrant and allowed such directors and officers to participate in the November 2024 Private Offering in accordance with the rules of the Nasdaq. The Series A Private Warrants have an exercise price of $1.75 per underlying Common Share, are exercisable immediately, and will expire on November 13, 2026. The Series B Private Warrants have an exercise price of $2.07 per underlying Common Share, are exercisable beginning six months and one day from the date of issuance and will expire on November 13, 2029. The Company recorded a non-cash expense of $34 and $110 to other operating expenses and employee related costs, respectively, representing the excess of fair value of the November 2024 Units over the purchase price paid by Insider Investors. | On November 5, 2024, the Company closed an underwritten public offering (the “November 2024 Registered Offering”), pursuant to the underwriting agreement, dated November 3, 2024 (the “November 2024 Underwriting Agreement”), with Maxim, as underwriter, which consisted of 1,592,356 Common Shares, 1,672,090 Warrants (the “Series A Public Warrants”) to purchase up to an additional 1,672,090 Common Shares and 836,045 Warrants (the “Series B Public Warrants” and, together with the Series A Public Warrants, the “November 2024 Public Warrants”) to purchase up to an additional 836,045 Common Shares. Each Common Share was sold together with one Series A Public Warrant and one-half of one Series B Public Warrant at a combined public offering price of $1.57. The gross proceeds from the November 2024 Registered Offering were $2,501 before deducting underwriting discounts and offering expenses. The November 2024 Public Warrants were classified as equity instruments and accordingly, the net proceeds were allocated based on the relative fair values of the Common Shares and the November 2024 Public Warrants on the date of issuance, with $943 allocated to the fair value of the November 2024 Public Warrants and the balance of the proceeds of $1,558 allocated to Common Shares. The Company incurred total transaction costs related to the November 2024 Registered Offering of $1,226, which were treated as share issuance costs at closing. The Series A Public Warrants have an exercise price of $1.75 per underlying Common Share, are exercisable immediately, and will expire on November 5, 2026. The Series B Public Warrants have an exercise price of $2.07 per underlying Common Share, are exercisable beginning six months and one day from the date of issuance and will expire on November 5, 2029. In addition, pursuant to the November 2024 Underwriting Agreement, the Company granted Maxim a 45-day over-allotment option to purchase (i) 238,853 additional Common Shares and (ii) 358,280 Option Warrants (as defined below) to purchase up to an aggregate of 358,280 Common Shares. “Option Warrant” means one Series A Public Warrant combined with one-half of one Series B Public Warrant. On November 4, 2024, Maxim partially exercised its over-allotment option to purchase 79,734 additional Series A Public Warrants and 39,867 additional Series B Public Warrants, which amounts are included in the amounts discussed above and were issued at closing of the November 2024 Registered Offering. | ||||||||||||||||||||||
| Common share exercise price, per share | $ / shares | $ 9.94 | |||||||||||||||||||||||
| Fair value of non operating gain/loss | $ | $ 1,928,000 | |||||||||||||||||||||||
| Registered Offering | $ | $ 799,000 | $ 161,000 | ||||||||||||||||||||||
| Private Offering | $ | $ 60,000 | |||||||||||||||||||||||
| Other operating expenses | $ | $ 34,000 | |||||||||||||||||||||||
| Employee related costs | $ | $ 110,000 | |||||||||||||||||||||||
| Percentage of Warrant Exercise on Ownership of Common Shares | 19.90% | 19.90% | ||||||||||||||||||||||
| Exchange of 2023 Private Warrants for 2023 Public Warrants | NioCorp Assumed Warrant Agreement, through June 30, 2026, a total of 3,447,246 2023 Private Warrants were exchanged for 2023 Public Warrants. The Company recorded a non-cash loss of $1,217 and $26 for the years ending June 30, 2026 and 2025, respectively, in change in fair value of warrant liabilities in the consolidated statement of operations, representing the change in fair value of the 2023 Private Warrants through the respective exercise dates. | |||||||||||||||||||||||
| Number of Warrants Exchanged | 3,447,246 | |||||||||||||||||||||||
| Stock issued, shares | 2,816,742 | |||||||||||||||||||||||
| Non-cash loss | $ | $ 1,217,000 | $ 26,000 | ||||||||||||||||||||||
| Number of shares exercised | 567,000 | 512 | ||||||||||||||||||||||
| Fair value adjustment for warrants exercised | $ | $ 0 | $ 144,000 | ||||||||||||||||||||||
| Beneficial ownership percentage | 20.00% | |||||||||||||||||||||||
| April 2024 Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Fair value adjustment for warrants exercised | $ | $ (1,807,000) | |||||||||||||||||||||||
| Private Placement [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Shares issue | 2,199,602 | |||||||||||||||||||||||
| Over Allotment Option [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Additional common shares authorised | 323,504 | 238,853 | ||||||||||||||||||||||
| Warrants issued | 358,280 | |||||||||||||||||||||||
| Purchase Agreement [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Common share exercise price, per share | $ / shares | $ 3.25 | $ 3.25 | ||||||||||||||||||||||
| Number of shares exercised | 615,385 | |||||||||||||||||||||||
| Warrant determination percentage | 25.00% | 25.00% | ||||||||||||||||||||||
| Lind Global Asset Management III, LLC [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Contingent consideration description | As consideration for entering into the previously publicly disclosed Waiver and Consent Agreement, dated September 25, 2022 (the “Lind Consent”), between the Company and Lind Global Asset Management III, LLC (“Lind III”), Lind III received, amongst other things, the right to receive additional Warrants (the “Contingent Consent Warrants”) if on September 17, 2024, the closing trading price of the Common Shares on the Toronto Stock Exchange or such other stock exchange on which such shares may then be listed, is less than C$10.00, subject to adjustments. The number of Contingent Consent Warrants to be issued, if any, is based on the Canadian dollar equivalent (based on the then current Canadian to U.S. dollar exchange rate as reported by Bloomberg, L.P.) of $5,000 divided by the five-day volume weighted average price of the Common Shares on the date of issuance. Further, the number of Contingent Consent Warrants issued would be proportionately adjusted based on the percentage of Warrants currently held by Lind III that are exercised, if any, prior to the issuance of any Contingent Consent Warrants. | |||||||||||||||||||||||
| Unsecured Debt [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Aggregate principal amount | $ | $ 8,000,000 | |||||||||||||||||||||||
| November 2024 Registered Offering [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Common stock, shares issued | 1,592,356 | |||||||||||||||||||||||
| Combined public offering price per unit | $ | $ 1.57 | |||||||||||||||||||||||
| Gross proceeds from offering | $ | 2,501,000 | |||||||||||||||||||||||
| Transaction cost | $ | $ 1,226,000 | |||||||||||||||||||||||
| Common stock share purchased | 358,280 | |||||||||||||||||||||||
| November 2024 Private Offering [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Combined public offering price per unit | $ | $ 1.57 | $ 1.57 | ||||||||||||||||||||||
| Gross proceeds from offering | $ | $ 3,500,000 | |||||||||||||||||||||||
| November 2024 Private Warrant [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Offering price of common shares issued in offering | $ / shares | $ 0.1975 | $ 0.1975 | ||||||||||||||||||||||
| January 2025 Offering [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Number of share outstanding | 1,288,660 | |||||||||||||||||||||||
| Combined public offering price per unit | $ | $ 1.94 | |||||||||||||||||||||||
| Gross proceeds from offering | $ | $ 5,000,000 | |||||||||||||||||||||||
| Warrants outstanding | 1,288,660 | |||||||||||||||||||||||
| April 2025 Offering [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Common stock, shares issued | 6,628,846 | |||||||||||||||||||||||
| Offering price of common shares issued in offering | $ / shares | $ 2.5999 | |||||||||||||||||||||||
| Net Proceeds | $ | $ 18,076,000 | |||||||||||||||||||||||
| Number of share outstanding | 1,063,462 | |||||||||||||||||||||||
| Gross proceeds from offering | $ | 20,841,000 | |||||||||||||||||||||||
| Net proceeds | $ | 2,765,000 | |||||||||||||||||||||||
| Transaction costs | $ | $ 2,102,000 | |||||||||||||||||||||||
| Warrants outstanding | 1,063,462 | |||||||||||||||||||||||
| GXII Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Number of share outstanding | 9,999,959 | |||||||||||||||||||||||
| Warrants outstanding | 9,999,959 | |||||||||||||||||||||||
| G X I I Private Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Number of share outstanding | 5,666,667 | |||||||||||||||||||||||
| Warrants outstanding | 5,666,667 | |||||||||||||||||||||||
| Lind Consent Warrant Issuance [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Common share exercise price, per share | $ / shares | $ 2.308 | |||||||||||||||||||||||
| Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants | $ | $ 5,000,000 | |||||||||||||||||||||||
| Warrant [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Issuance of warrants | 2,600,000 | 5,925,000 | 2,755,260 | |||||||||||||||||||||
| Offering price per share | $ / shares | $ 4.9999 | $ 9.3399 | $ 6.1499 | |||||||||||||||||||||
| Number of share outstanding | 18,707,780 | 29,985,922 | 18,563,561 | |||||||||||||||||||||
| Warrants outstanding | 18,707,780 | 29,985,922 | 18,563,561 | |||||||||||||||||||||
| Description of warrants | Each NioCorp Assumed Warrant entitles the holder to the right to purchase 1.11829212 Common Shares at an exercise price of $11.50 per 1.11829212 Common Shares (subject to adjustments for stock splits, stock dividends, reorganizations, recapitalizations and the like). | |||||||||||||||||||||||
| Common share exercise price, per share | $ / shares | $ 7.06 | $ 10.53 | ||||||||||||||||||||||
| Common Stock [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Gross proceeds from offering | $ | $ 1,558 | |||||||||||||||||||||||
| Warrant exchange ratio | 1.11829% | |||||||||||||||||||||||
| Remaining proceeds from private warrants | $ | $ 2,800,000 | $ 1,573,000 | ||||||||||||||||||||||
| Number of shares exercised | 486,452 | 512 | ||||||||||||||||||||||
| November 2024 Public Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Gross proceeds from offering | $ | $ 943,000 | |||||||||||||||||||||||
| January 2025 Series A Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Number of share outstanding | 2,577,320 | |||||||||||||||||||||||
| Warrant exercise price | $ / shares | $ 0.0001 | $ 1.98 | ||||||||||||||||||||||
| Warrants outstanding | 2,577,320 | |||||||||||||||||||||||
| January 2025 Series B Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Warrant exercise price | $ / shares | $ 2.05 | |||||||||||||||||||||||
| January 2025 Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Gross proceeds from offering | $ | $ 2,200,000 | |||||||||||||||||||||||
| Series A Public Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Issuance of warrants | 1,672,090 | |||||||||||||||||||||||
| Number of share outstanding | 1,672,090 | |||||||||||||||||||||||
| Warrant exercise price | $ / shares | $ 1.75 | |||||||||||||||||||||||
| Warrants outstanding | 1,672,090 | |||||||||||||||||||||||
| Series A Public Warrants [Member] | Over Allotment Option [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Warrants issued | 79,734 | |||||||||||||||||||||||
| Series B Public Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Issuance of warrants | 836,045 | |||||||||||||||||||||||
| Number of share outstanding | 836,045 | |||||||||||||||||||||||
| Warrant exercise price | $ / shares | $ 2.07 | |||||||||||||||||||||||
| Warrants outstanding | 836,045 | |||||||||||||||||||||||
| Series B Public Warrants [Member] | Over Allotment Option [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Warrants issued | 39,867 | |||||||||||||||||||||||
| Series A Private Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Warrant exercise price | $ / shares | 1.75 | |||||||||||||||||||||||
| Series A Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Issuance of warrants | 2,577,320 | |||||||||||||||||||||||
| Series B Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Issuance of warrants | 1,288,660 | |||||||||||||||||||||||
| Series B Private Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Warrant exercise price | $ / shares | $ 2.07 | |||||||||||||||||||||||
| February 2026 Pre-Funded Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Common stock, shares issued | 2,599,951 | 2,599,951 | ||||||||||||||||||||||
| Pre-Funded Warrants [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Issuance of warrants | 1,063,462 | |||||||||||||||||||||||
| Number of share outstanding | 2,600,000 | |||||||||||||||||||||||
| Warrants outstanding | 2,600,000 | |||||||||||||||||||||||
| 2023 Public Warrants | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Number of share outstanding | 13,447,105 | |||||||||||||||||||||||
| Warrants outstanding | 13,447,105 | |||||||||||||||||||||||
| Description of warrants | (ii) the last reported sale price of the Common Shares equals or exceeds approximately $16.10 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the Warrant holders | |||||||||||||||||||||||
| Common share exercise price, per share | $ / shares | $ 0.01 | |||||||||||||||||||||||
| Redemption notice period days | 30 days | |||||||||||||||||||||||
| Stock price threshold | $ / shares | $ 16.1 | |||||||||||||||||||||||
| Requirement of trading days | TradingDays | 20 | |||||||||||||||||||||||
| Warrant Liability [Member] | ||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||||||||||||||
| Gain on issuance of Warrants | $ | $ 103,000 | $ (103,000) | ||||||||||||||||||||||
| Fair value adjustment for warrants exercised | $ | $ 2,262,000 | $ (2,262,000) | ||||||||||||||||||||||